77 results about "Infectious agent" patented technology

An intermediate article has a non-electrically conductive substrate having first and second opposing surfaces; and a catalytic ink disposed as a pattern of half-tone dots on at least the first opposing surface. Copper metal can be plated on the pattern of catalytic ink to provide a copper metal pattern that have antimicrobial properties. The resulting antimicrobial article can then be applied to various surfaces to mitigate the spread of infectious agents from one person to another.

According to certain embodiments, the present disclosure provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds a target antigen and a second antigen binding domain that binds a complement component. In certain embodiments, the bispecific antigen-binding molecules of the present disclosure are capable of binding to the target antigen with an EC50 of about 10 nM or less, and / or are capable of promoting complement deposition on the target antigen with an EC50 of about 10 nM. In certain embodiments, the bispecific antigen-binding molecules of the disclosure are useful for treating diseases in which inhibition or reduction of the growth of an infectious agent or cancer cell is desired and / or therapeutically beneficial.

The present disclosure relates to the field of RNAs for the prevention or treatment of various infectious agents. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection, influenza infection and / or RSV infection and induction of effective coronavirus, influenza virus and / or RSV antigen-specific immune responses, such as antibodies and / or T cell responses. Specifically, in one embodiment, the disclosure relates to a method comprising administering to a subject (i) a bivalent RNA vaccine encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein), and (ii) a tetravalent RNA vaccine encoding a peptide or protein comprising an epitope of hemagglutinin (HA), the present invention relates to a method for inducing an immune response in a subject against a coronavirus S protein, in particular an S protein of SARS-CoV-2, and an influenza protein, in particular an HA protein of influenza A and B viruses.

The invention provides a method of preparing a vaccine composition. The method includes infecting gene-edited porcine endogenous retrovirus (PERV) negative swine cells with a microorganism which expresses at least one protein antigen capable of inducing protective immunity in an animal against an infectious agent; culturing the infected cells in culture medium to propagate the microorganism; and harvesting the propagated microorganism from the culture medium to obtain a fraction comprising a PERV free antigen for use in immunizing an animal against the infectious agent.

The present invention relates to the treatment of viral infections using photosensitizers in dairy cattle. The invention also relates to the prevention of transmission of viral infections from dairy cattle infected by virus to the same or other species. The invention is also directed to methods of controlling infectious agents on milking equipment for dairy cattle. The invention is further directed to milking processes including the treatment of viral infections and / or the prevention of transmission of viral infections from dairy cattle infected by virus to the same or other species and / or the methods for controlling infectious agents on milking equipment for dairy cattle.

The invention provides a method of preparing a vaccine composition. The method includes infecting gene-edited porcine endogenous retrovirus (PERV) negative swine cells with a microorganism which expresses at least one protein antigen capable of inducing protective immunity in an animal against an infectious agent; culturing the infected cells in culture medium to propagate the microorganism; and harvesting the propagated microorganism from the culture medium to obtain a fraction comprising a PERV free antigen for use in immunizing an animal against the infectious agent.

The present disclosure relates generally to compositions, systems, and methods for lysing blood samples comprising an infectious agent, for example a bacteria, or a fungus, while maintaining viability of the infectious agent for subsequent characterization, for example phenotyping or genotyping. A lysing composition may include one or more surfactants, such as one or more detergents. A lysing composition may include lysing agent including one or more salts. A lysing composition may include one or more enzymes to break down one or more lyses byproducts, such as nucleic acids and / or protein aggregates.

A device for safely and effectively disinfecting a catheter while it remains implanted in a patient's body is provided. [Solution] Methods and devices for providing therapeutic electromagnetic radiation (EMR) to inactivate infectious agents and / or enhance healthy cell growth in, on, or around a catheter (10) placed in a patient's body cavity. Non-ultraviolet therapeutic EMR is transmitted axially along the lumen of the catheter body and / or along an optical element (14) within the catheter body. Delivery of the therapeutic EMR to specific infected areas and / or areas requiring tissue healing results in inactivation of primary sources of infection in, on, and around the catheter and / or enhancement of healthy cell growth around the catheter through the use of controlled relative intensity and treatment-site-specific dose projection of the therapeutic EMR radially emitted from the optical element. Specific embodiments for urinary catheters and peritoneal dialysis catheters are also disclosed.

Methods are provided for predicting a subject's infection status using high-throughput T cell receptor sequencing to match the subject's TCR repertoire to a known set of disease-associated T cell receptor sequences. The methods of the present invention may be used to predict the status of several infectious agents in a single sample from a subject. Methods are also provided for predicting a subject's HLA status using high-throughput immune receptor sequencing.

The application provides a primer probe set, a kit and application for quantitatively detecting murine infectious agents, and belongs to the technical field of genetic engineering.The six-reagent quantitative detection kit (fluorescent PCR method) for tsutsugamushi oriental body, fever with thrombocytopenia syndrome virus, prrillonella, hantavirus, leptospira, and rickettsia mooseri can detect the six pathogenic targets of tsutsugamushi oriental body, fever with thrombocytopenia syndrome virus, prrillonella, hantavirus, leptospira, and rickettsia mooseri in one reaction, and accurately quantitatively analyzes each pathogenic target.Through single-tube reaction, parallel detection and quantification of the six pathogenic targets are realized, the time consumed due to misjudgment of the targets is reduced, the consumption of consumables and the occupation of instrument space caused by multi-tube reaction are reduced.The quantitative results reflect the pathogenic load, and provide efficient detection and application support for rapid identification and quantitative monitoring of samples of murine origin or samples of the environment related to mouse activities.

A device for reducing a level of infectious agents present on one or more hands of a user. This device may reduce the level of infectious agents present on one or more fingers and / or thumbs of a user, specifically reducing a level of infectious agents present on the distal aspect of the digit; including, but not limited to an underside of a nail plate, and an area of hyponychium skin between a free margin of the nail plate and an onychodermal band of a digit, such as for example, a finger, thumb, or toe.

The application discloses a modified crRNA, a light-controlled nucleic acid detection system, a kit and application, and belongs to the cross field of biotechnology, intelligent sensing and molecular diagnosis. In view of the technical defects of strong target sequence dependence and high ultraviolet irradiation requirement of the existing light-controlled CRISPR technology, the application innovatively introduces a photosensitive protection group 6-nitropiperidin oxymethyl (NPOM) at a specific key node of a stem loop skeleton of crRNA maintaining conformation. In the constant temperature amplification stage, preferred double-site cooperative modification can transiently inhibit RNP complex assembly to realize target non-interference enrichment; subsequently, only 10 mW / cm 2 of extremely low intensity ultraviolet light irradiation for 30 seconds can restore the crRNA conformation and activate the trans cleavage. The preferred technical scheme of the application can eliminate the target sequence limitation, realizes a detection limit of as low as 2 copies in a single reaction tube, and the result can be obtained within 15 minutes. The system is widely applicable to rapid diagnosis of infectious agents, high-specificity typing of single nucleotide polymorphism and portable intelligent molecular diagnosis terminal.

The application provides a kind of detection system of infectious pathogen type based on 5 markers, the 5 markers include: GSDMD, p-MLKL, IL-6, PCT, CRP, the system includes the following modules: (1) detection model: the GSDMD of detection sample, p-MLKL, IL-6, PCT, CRP content;(2) analysis module: based on random forest algorithm, neural network algorithm is analyzed to data, constructs diagnosis bacterial infection model;(3) diagnosis module: based on machine learning algorithm model is judged to bacterial infection to be diagnosed sample.The system provided by the application reaches 0.909, the diagnostic accuracy rate, the sensitivity, specificity, positive predictive value and negative predictive value of diagnosis are as follows: 0.95, 0.85, 0.90, 0.92.

Disclosed herein are methods and systems for rapid detection of microorganisms, such as bacteria, in a sample. Also disclosed is a genetically modified bacteriophage comprising an indicator gene encoding one subunit of an indicator protein. The specificity of the bacteriophage allows detection of specific target bacteria, and the indicator signal can be amplified to optimize assay sensitivity.

Provided herein are vaccine compositions for use in the stimulation of broad-spectrum memory B cell expansion in a patient that has been exposed or is at risk of exposure to an infectious agent of unknown etiology. The composition comprises IL-15 or an IL-15 analog and at least two toll-like receptor (TLR) agonists, wherein the agonists are targeted to different members of the TLR family. Further contemplated herein are compositions and methods of stimulating germinal B cell expansion in a patient, the composition comprising IL-15 or an IL-15 analog and a nucleic acid, wherein the nucleic acid encodes at least one immunogenic peptide, and wherein the composition is administered either subcutaneously or directly into a lymph node.

In the present invention, cyclic dinucleotides or their compositions are used as biological response modifiers to enhance the immune response of subjects with deficient immune systems, with a low or absent response to vaccine antigens, or with a deficient immune response to pathogens. The formulations of the present invention are capable of modifying the biological response in such a way as to eliminate the lack of response, resulting in the development of a high-avid immune response that prevents disease caused by infectious agents, particularly viruses with the ability to evade immune surveillance mechanisms and, consequently, suppress the induction of an effective, high-avid adaptive response.The present invention also comprises cyclic dinucleotide formulations, which can be administered alone, in combination with other biological response modifiers, or in vaccine formulations with antigens. The proposed invention further includes a method for preventing or treating acute respiratory infections, preventing disease severity, and blocking transmission by inducing an immune response at the point of entry (nasopharyngeal mucosa), preventing or reducing person-to-person transmission of pathogens / viruses in preventive vaccine formulations, as well as in formulations used for prophylaxis before and after exposure to acute respiratory infections.

Disclosed herein are methods and systems for rapid detection of microorganisms in a sample without enrichment culture of the microorganisms. Also disclosed is a modified bacteriophage comprising a non-natural indicator gene in the late gene region. The indicator product is not a fusion protein. The specificity of infectious agents allows targeting of specific microorganisms, and the indicator signal can be enlarged to optimize assay sensitivity.

This invention discloses the application of 6-methyladenine in the preparation of drugs against Pseudomonas aeruginosa infection. This invention provides the application of 6-methyladenine in the preparation of drugs against Pseudomonas aeruginosa (… Pseudomonas aeruginosa Application in infectious agents. The 6-methyladenine described in this invention inhibits the quorum sensing of Pseudomonas aeruginosa and the production of related virulence factors, thereby suppressing Pseudomonas aeruginosa infection in vivo and in vitro, reducing host mortality, and providing a new therapeutic strategy for the prevention and control of Pseudomonas aeruginosa infection.

A method for operating infection-control air-conditioning according to a concentration of airborne infectious agents according to the present disclosure may comprise the steps of: collecting air quality data of a target space in which one or more infection-control air-conditioning devices are disposed; calculating prediction data associated with a concentration of airborne infectious agents in the target space on the basis of the air quality data; and controlling an operating condition of the infection-control air-conditioning devices on the basis of the prediction data.

An intermediate article has a non-electrically conductive substrate having first and second opposing surfaces; and a catalytic ink disposed as a pattern of half-tone dots on at least the first opposing surface. Copper metal can be plated on the pattern of catalytic ink to provide a copper metal pattern that have antimicrobial properties. The resulting antimicrobial article can then be applied to various surfaces or objects to reduce, mitigate, or inhibit the spread of infectious agents from one person to another from human touching the surfaces or objects.

The invention relates to vaccination with immune-isolated cells producing immunomodulators. Provided herein are vaccine compositions containing at least one retrievable biocompatible macrocapsule containing immune-isolated allogeneic cells that secrete an immunomodulator, such as GM-CSF (granulocyte-macrophage colony stimulating factor), and an antigen component (e.g., autologous tumor cells or infectious factors). Also provided herein are kits and pharmaceutical compositions containing the vaccine compositions and said products for use in methods of therapeutic or prophylactic vaccination against tumors or infectious factors.

The present disclosure details various lipids, compositions, and / or methods of optimized systems and delivery vehicles for the delivery of nucleic acid sequences, polypeptides or peptides for use in vaccinating against infectious agents.

The invention relates to a method of treating a disease or disorder in a patient in need thereof that includes providing an active pharmaceutical ingredient (API) to the patient by administering more than one split-dose of the API over a pre-determined period of time. In embodiments of the invention, the API is an mRNA encoding an antigen. The attractiveness of mRNA as a vaccine modality is supported by several advantages. As a non-infectious agent that does not require incorporation into the host's genome to confer activity along with its well-defined chemical composition, mRNA is regarded as a relatively safe vaccine modality.

The present disclosure provides nanostructures and nanostructure-based vaccines. Some nanostructures of the present disclosure display antigens capable of eliciting an immune response to infectious agents such as bacteria, viruses, and pathogens. Some vaccines of the present disclosure are useful for preventing or reducing the severity of infection by infectious agents including, but not limited to, Lyme disease, pertussis, herpes virus, orthomyxovirus, paramyxovirus, pneumovirus, filovirus, flavivirus, reovirus, retrovirus, meningococcus, or malaria. The antigens can be attached to the core of the nanostructure non-covalently or covalently, including as a fusion protein or by other means disclosed herein. Multimeric antigens can optionally be displayed along the symmetry axis of the nanostructure. Also provided are proteins and nucleic acid molecules encoding such proteins, vaccine compositions, and methods of administration.

Methods of generating memory T cells in vitro are provided. The methods include culturing a population of T cells with a population of antigen-loaded dendritic cells for at least about 28-48 days in a culture medium and isolating memory T cells (such as CD4+ or CD8+ memory T cells) from the culture. Methods of treating a subject with cancer or infectious disease are also provided. The methods include administering to the subject memory T cells generated by the methods described herein, where the antigen-loaded dendritic cells are loaded with an antigen expressed by the cancer or the infectious agent causing the disease. Also provided are methods of identifying T cell receptors that specifically bind to an antigen recognized by a memory T cell, which include producing a population of memory T cells recognizing an antigen as described herein, and identifying the T cell receptor expressed by the memory T cells.

The present invention relates to the field of immunotherapy, in particular to diseases associated with Epstein-Barr virus (EBV, also known as human gamma herpesvirus 4), such as cancer or post-transplant lymphoproliferative disease, in particular to adoptive T cell therapy or T cell receptor (TCR) gene therapy. The present invention provides a combination of nucleic acids encoding at least two TCR constructs or corresponding proteins or host cells, wherein each TCR construct is capable of specifically binding to its respective epitope in the context of a respective MHC I, and wherein the epitopes are derived from different antigens expressed by the same infectious agent or cancer, such as EBV antigens. The present invention further provides specific nucleic acids encoding a TCR alpha chain construct (TRA) and / or a TCR beta chain construct (TRB) of a TCR construct specific for an epitope complexed with human MHC I, wherein the epitope is an epitope of an Epstein-Barr virus protein, the TCR construct being specific for an epitope from LMP2A, LMP1 or EBNA3C. Proteins encoded by said nucleic acids, corresponding host cells, as well as pharmaceutical compositions and kits are also an object of the present invention.

Abstract Provided herein are multi-domain immunomodulatory proteins, nucleic acids encoding such immunomodulatory proteins, cells engineered to express the immunomodulatory proteins and infectious agents containing nucleic acid encoding the immunomodulatory proteins. The immunomodulatory proteins bind both an inhibitory receptor and a receptor involved in activation signaling cascades in an immune cell, such as a T cell. The immunomodulatory proteins, engineered cells and infectious agents provide therapeutic utility for a variety of immunological diseases or conditions. Compositions and methods for making and using such proteins are provided. Abstract 20 26 21 41 08 10 A ug 2 02 6 A b s t r a c t 2 0 2 6 2 1 4 1 0 8 1 0 A u g 2 0 2 6

Novel, nanoparticle-based vaccines are provided that elicit an immune response to a broad range of infectious agents, such as influenza viruses. The nanoparticles comprise a heterogeneous population of fusion proteins, each comprising a monomeric subunit of a self-assembly protein, such as ferritin, joined to one or more immunogenic portions of a protein from an infectious agent, such as influenza virus. The fusion proteins self-assemble to form nanoparticles that display a heterogeneous population of immunogenic portions on their surface. When administered to an individual, such nanoparticles elicit an immune response to different strains, types, subtypes and species within the same taxonomic family. Thus, such nanoparticles can be used to vaccinate an individual against infection by different Types, subtypes and / or strains of infectious agents. Also provided are specific fusion proteins, nucleic acid molecules encoding such fusion proteins and methods of using nanoparticles of the invention to vaccinate individuals.

1. Name of the product in this design: Dental Aerosol Adsorption and Disinfection Integrated Machine. 2. Purpose of this design: This device can be used to handle splashes, droplets and aerosols generated during oral treatment procedures, as well as the infectious agents contained therein. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the design's key features: the front view.

Embodiments of the present disclosure are directed to systems and methods for collection and analysis of environmental air dust (EAD) within an individually ventilated cage rack (IVR) environment for detecting pathogens. The method includes collection of an EAD sample by a collection media, isolation of a plurality of nucleic acids (e.g., RNA and / or DNA) representative of one or more infectious agents from the EAD sample, optional reverse transcription of RNA to cDNA if the isolated nucleic acids contain RNA, amplification of the cDNA and / or DNA (e.g., by polymerase chain reaction (PCR)), and assay interpretation. Optionally, the EAD sample may be analyzed with one or more other sample types (e.g., fecal pellets, oral swabs, body swabs, tissue, etc.) to improve detection of low-copy organisms.